- Bluebird Bio shares are trading higher Monday after the company presented updated data from its gene therapy program.
- The news comes after Bluebird Bio shares tumbled on Friday.
- This simple system has nailed 1,000+ post-earnings winners. Get in before Q3 trades take off →
Bluebird Bio Inc BLUE shares are trading higher Monday after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
What Happened: Bluebird Bio said the data showed sustained treatment effect, reduced iron management burden and improved quality of life measures in patients with beta-thalassemia who require regular red blood cell transfusions following treatment with betibeglogene autotemcel, which is FDA approved in the U.S. and marketed as ZYNTEGLO.
"Long-term results presented at ASH 2023 showed durable transfusion independence and a continued positive safety profile in patients with beta-thalassemia treated with our beti-cel gene therapy through up to nine years of follow-up," said Richard Colvin, chief medical officer of Bluebird Bio.
The news comes after Bluebird Bio shares tumbled on Friday after the FDA added a black box warning for patients treated with Lyfgenia regarding the risk of hematologic malignancy.
BLUE Price Action: Bluebird Bio shares were up 2.45% at $2.93 at the time of publication, according to Benzinga Pro.
Photo: 3844328 from Pixabay.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.